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Abstract: 
Cholera is a global disease that has persisted for millennia. The cholera toxin (CT) from Vibrio cholerae is responsible for the clinical symptoms of cholera. This 
toxin is a hetero-hexamer (AB5) complex consisting of a subunit A (CTA) with a pentamer (B5) of subunit B (CTB). The importance of the AB5 complex for 
pathogenesis is established for the wild type O1 serogroup using known structural and functional data. However, its role is not yet documented in other known 
serogroups harboring sequence level residue mutations. The sequences for the toxin from different serogroups are available in GenBank (release 177). Sequence 
analysis reveals mutations at several sequence positions in the toxin across serogroups. Therefore, it is of interest to locate the position of these mutations in the 
AB5 structure to infer complex assembly for its functional role in different serogroups. We show that mutations in the CTA are at the solvent exposed regions of 
the AB5 complex, whereas those in the CTB are at the CTB/CTB interface of the homo-pentamer complex. Thus, the role of mutations at the CTB/CTB interface 
for B5 complex assembly is implied. It is observed that these mutations are often non-synonymous (e.g. polar to non-polar or vice versa). The formation of the AB5 
complex involves inter-subunit residue-residue interactions at the protein-protein interfaces. Hence, these mutations, at the structurally relevant positions, are of 
importance for the understanding of pathogenesis by several serogroups. This is also of significance in the improvement of recombinant CT protein complex 
analogs for vaccine design and their use against multiple serogroups.  
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Background: 
Vibrio cholerae is the cause of a waterborne disease affecting thousands of life 
every year [1]. The outbreak in October, 2010, in Haiti demonstrates the global 
issue of cholera and resulted in approximately 1,000 deaths within a month [2]. 
Cholera is an acute diarrheal disease caused by the gram-negative bacterium, 
Vibrio cholerae. There are more than 200 serogroups of Vibrio cholerae 
present in the natural environment [3]. However, two serogroups, O1 
(widespread with El Tor and classical biotypes) and O139 (colonizes few 
regions of Asia) have been associated with the epidemics and pandemics of 
cholera during the last 25 years [4-6]. The O1 (El Tor biotype – Ogawa 
serotype) serogroup is responsible for the recent outbreak in Haiti [7]. The 
symptoms of cholera are caused by the secretion of an entero-toxin called 
cholera toxin (CT) [8-9] which is encoded by virulence factor genes; ctxA and 
ctxB  [10-11]. These genes are acquired from a lysogenic filamentous 
bacteriophage (CTXΦ) through CTXΦ DNA integration into the host Vibrio 
cholerae genome [12-14]. It should be noted that the incidence of cholera 
outbreaks with serogroups other than O1/O139 (collectively referred as non 
O1/non O139) has also been recorded [5, 10, 15-17]. These strains are 
responsible for the sporadic outbreaks [18-22]. It is known that the virulent 
factors for non-(O1/O139) are different from the O1/O139 strains [5, 23, 24]. 
However, non-(O1/O139) strains with ctxA and ctxB genes also have been 
observed [25-28].  
 
CT, also known as choleragen, is a hetero-hexameric AB5 complex in structure 
(Figure 1) [29-31] and is composed of an enzymatic A subunit (CTA) and a 
cell targeting B subunit (CTB) [32-34]. The enzymatically activated A subunit 
catalyzes adenylate cyclase to cause massive excretion of electrolytes from 
bowel  [35, 36].  However, the homo-pentamer B subunit is mandatory for 
pathogenesis because of its vital role in binding to receptors of target cells [37-
39]. The B complex binds to the intestinal epithelium and the A molecule then 
detaches and enters the cell via endocytosis. The A molecule then goes onto 
ribosylating the Gs alpha-subunit of G proteins that results in constitutive 
production of cAMP. The result is excretion of bicarbonate, chloride, 
potassium, and sodium ions as well as water from these cells [40]. Thus, the 
AB5 complex assembly is critical for pathogenesis. The virulence factors in 
both O1/O139 and non-(O1/O139) strains have been identified [8, 9, 16, 17, 
24, 28, 41]. It should be noted that information on the diarrheagenic potential 
of non-(O1/O139) is limited. The effect of mutations in the toxin from all BIOINFORMATION  open access 
 
ISSN 0973-2063 (online) 0973-8894 (print)     
Bioinformation 6(1): 1- 9 (2011)                          © 2011 Biomedical Informatics 
 
 
2
known serogroups is not available. Therefore, it is of importance to describe 
the virulence factors in both O1/O139 and non-(O1/O139). This is possible 
with the help of known structural complexes available in Protein databank 
(PDB). A comprehensive analysis of the AB5 CT structures from PDB 
describing the nature of A and B5 interface has been documented elsewhere 
[42]. Here, we describe the significance of mutations in CT among serogroups 
based on their residue positional occurrence (either at solvent exposed or 
interface regions of the AB5 complex). 
 
 
Figure 1: Structural model of a cholera toxin (CT). CT is a hetero-hexameric 
complex (AB5) consisting of CTA (194 residues A1 and 46 residues A2) and 
CTB (103 residues) pentamer with D, E, F, G and H chains.  
 
Materials and Methodology: 
CT sequence dataset: 
We created a dataset of 27 CTA (O1: 14; O139: 5; non-O1/O139: 8) and 165 
CTB (O1: 121; O139: 37; non-O1/O139: 7) sequences as available from 
GenBank (release 177; year 2010 [43] using the procedure outlined in Figure 
2. The number of sequences in the datasets is stated in Table 1 (see 
Supplementary material). There are more CTB sequences than CTA 
sequences suggesting a higher frequency of mutations in CTB.  Some partial 
sequences have been included in the dataset due to the non-availability of their 
full-length sequences in GenBank.  In addition, these partial sequences also 
harbored mutations compared to wild type sequences.  
 
Multiple Sequence Alignment (MSA) of CTA and CTB: 
MSA is performed using ClustalX 2.0.12 [44] with the substitution matrix 
PAM 80. A gap-opening penalty of 10 and extension-penalty of 0.2 were used 
for the alignment. Sequences of CTA and CTB with known structures (PDB 
ID: 1XTC [45]) belonging to the O1 classical 569B strain were used as 
reference sequences in this alignment. The alignment was used to identify 
mutations in CTA (Figure 3) and CTB (Figure 4) among the different 
serogroups. Mutations were identified at six residue positions (7, 28, 112, 134, 
163 and 222) in CTA (Figure 3) and at 13 residue positions (3, 7, 13, 15, 18, 
22, 25, 34, 46, 47, 52, 60 and 94) in CTB (Figure 4) among O1/O139 and non-
(O1/O139) strains.  
 
CT structures: 
The formation of the AB5 complex is critical for pathogenesis. This is achieved 
through the formation of B5 and AB5 complexes. The B5 complex is formed 
through the assembly of 5 monomeric B subunits arranged in a circle with a 
central groove in the first stage. This results in an assembly with each B 
subunit juxtaposed on either side with two other B subunits with a stable 
interface as shown in Figure 5. Mutations in the B subunit and the potential 
occurrence at the CTB/CTB interface influence the formation of the B5 
complex. The formation of AB5 complex occurs through the interaction of 
CTA and B5 complex. Thus, mutations in either CTA or CTB among the 
different serogroups have effect at the interface of CTA/ CTB complex. 
 
Interface residues: 
Interface residue positions were identified using the change in solvent 
accessible surface area (ASA) upon complex formation from a monomer state 
to a dimer state both within B5 complex and between CTA/CTB. ASA is 
calculated using an algorithm developed by Lee and Richard (1971) 
implemented in the software SURFACE RACER with a probe radius of 1.4 Å 
[46]. We identified the interface residues between CTA/CTB complex and 
within the B5 complex in respective serogroups using the procedure described 
elsewhere [42]. In this procedure, interface residue positions were identified 
using ASA analysis of subunits in the AB5 structural complexes. 
 
 
Figure 2: Creation of sequence dataset for CTA and CTB. A sequence dataset 
of CTA and CTB was derived from GenBank (release 177) using KEYWORD 
search as illustrated in the flowchart. The KEYWORD search “cholera toxin” 
resulted in 1257 hits. This set consists of 27 CTA sequences, 165 CTB 
sequences according to GenBank description and available annotations. The 
remaining 1065 sequences with descriptions such as secretion protein, cholera 
toxin transcriptional activator, ADP-ribosylation factor, GNAS complex, 
dopamine receptor, Pertusis toxin, Shiga-like toxin and the like are eliminated 
from the dataset. Thus, a CT sequence dataset of 192 sequences (Table 1) 
consisting of 27 CTA and 165 CTB was created. The CTA and CTB sequences 
are included in the dataset as available in the GenBank. The biased availability 
on the amount of CTA and CTB sequences in GenBank is attributed to the 
likely observation of frequent mutations in CTB.  
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Figure 3: MSA for the CTA subunit of different serogroups. The MSA was performed using the wild type O1 classical strain sequence with known structure 
(PDB ID: 1XTC) as reference. The position specific mutations among the available CTA sequences (27) with reference to the classical sequence are indicated 
using dark shades. CT is an AB5 hetero-hexamer and hence, the CTA/CTB interface residues in CTA are indicated using light shades.  
 
 
Figure 4: MSA for the CTB subunit of different serogroups. The MSA was performed using the wild type O1 Classical strain with known structure (PDB ID: 
1XTC) as reference. The position specific mutations among the available CTB sequences (165) with reference to the Classical sequence are indicated using dark 
shades. B5 is a homo-pentamer and hence, the CTB/CTB interface residues in B5 are indicated using light shades. It should be noted that the mutated residues at 
the CTB/CTB interfaces in B5 are highlighted using both dark and light shades at their corresponding position specific residues.  BIOINFORMATION  open access 
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Mapping mutated residue positions to structures:   
The structures for AB5 and B5 complexes of the wild type O1 strain are 
available at the PDB. It is of interest to infer structural effect caused by the 
mutations in other known serogroups. It is well known that homologous 
sequences have similar structures and they differ only in side chain details. 
Therefore, mapping of mutated residue positions from MSA (Figure 3 and 
Figure 4) to known structural regions (exposed, buried, interface) provide the 
opportunity to identify mutations at the interface of CTA/CTB and within B5 
(Figure 6). This approach identified mutations (at six residue positions such as 
7, 28, 112, 134, 163 and 222) in CTA that are located at structurally solvent 
exposed regions of the complex (Figure 6a). It also helped to locate several 
mutations (seven residue positions such as 3, 15, 25, 34, 47, 52 and 60) in CTB 
that are at the B5 homo-pentamer subunit interfaces (Figure 6b and 6c). 
 
 
Figure 5: Structural model of CTB/CTB interfaces in B5. B5 is a homo-
pentamer and each CTB subunit (D) is juxtaposed by two other CTB units on 
either side (E and H). Thus, the D subunit creates two different types of 
interfaces (D-E and D-H) on either side. This subsequently results in two 
different “position specific interacting” patterns in sequence for subunit D. 
 
Structural 3D visualization of mutated residue positions in serogroups: 
We used Discovery Studio Visualizer (v2.5.5.9350) to illustrate the mutated 
residue positions in CTA (Figure 7a) and CTB (Figure 7b) among the 
serogroups. The mutated residue positions at the interface of CTA/CTB 
(Figure 8a) and with B5 (Figure 8b) is also shown.  
 
Results: 
Table 1 describes the dataset of CTA and CTB sequences retrieved from 
GenBank (release 177; year). The dataset consists of CTA and CTB sequences 
from O1 (El Tor, Classical, Matlab), O139 and non-(O1/O139) serogroups. We 
compared the CT sequences for O139 and non-(O1/O139) with the wild type 
Classical O1 serogroup. Figure 3 and Figure 4 show the results of MSA for 
CTA (27 sequences) and CTB (165 sequences), respectively. The wild type O1 
Classical sequence with known structure (PDB ID: 1XTC) from strain 569B 
was used as reference in the alignment. The alignment is showed only for 
sequences with mutations (7 CTA and 52 CTB mutants) to the wild type 
reference sequence (Figure 3 and Figure 4). The mutations observed from the 
MSA of known CTA and CTB sequences are summarized in Table 2 and 
Table 3 (see Supplementary material), respectively. The mutations in CTA 
are found at 6 residue positions (7, 28, 112, 134, 163 and 222) among 
serogroups in the dataset. The mutations in CTB sequences are at 13 residue 
positions (3, 7, 13, 15, 18, 22, 25, 34, 46, 47, 52, 60 and 94) in the dataset. 
 
Table 2 shows that the I222Y mutant is in the O139 strain (4260B) and the 
other six are in non-(O1/O139) strains. Data also shows that all strains except 
for strains B (2 positional mutations) and J31W (3 positional mutations) have 
only one positional mutation (Table 2 and Figure 3). Similarly, mutations 
were seen at one position in 18 strains (O1: 12; O139: 6), at two positions in 26 
strains (O1: 14; O139: 7; non-(O1/O139): 5), at 3 positions in 6 O1 strains, 4 
positions and 6 positions in one non-(O1/O139) strain for CTB (Figure 4 and 
Table 3). The non-(O1/O139) serogrouped J31W strain carried the maximum 
number of mutations in CT (CTA and CTB).  Thus, the position specific 
mutations for CTA and CTB sequences were observed. 
 
The availability of CT structure (PDB ID: 1XTC) provides an opportunity to 
map position-specific mutations in different serogroups to its structural 
preference (solvent exposed, buried, interfaces). Therefore, the significance of 
these mutations in the formation of the AB5 assembly could be subsequently 
inferred. The mutations (dark shades as background) in the CTA and the CTB 
are shown in Figure 3 and  Figure 4 along with corresponding interface 
residues (light shades). This helps to relate the consequence of mutations in 
structure. CT is an AB5 complex (Figure 1) consisting of several layers of 
subunit protein interfaces formed by non-covalent interactions. Therefore, it is 
of interest to map the mutations in serogroups to their structural positions 
(interior, interface, surface). 
 
 
Figure 6: Representation of mutated residue positions in serogroups to 
interface residues in CT complex as a function of their residue position 
identified using ∆ASA measure. (a) Mapping of CTA mutations to CTA/CTB 
interface residues in CTA (Please refer to Figure 1 for the visual illustration of 
CTA/CTB interface). (b) Mapping of CTB mutations to CTB (D subunit)/CTB 
(E subunit) interface residues (Please refer to Figure 5 for the visual 
illustration of D-E interface). (c) Mapping of CTB mutations to CTB (D 
subunit)/CTB (H subunit) interface residues (Please refer to Figure 5 for the 
visual illustration of D-H interface). It should be noted that mutated residue 
positions are mapped on to corresponding interface residue positions in all the 
three cases (a), (b) and (c). BIOINFORMATION  open access 
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Figure 7: Structural models of CTA (a) and CTB (b) subunits with known 
mutations among archived serogroups. We used the structure with PDB entry 
(1XTC) for generating this visual using the freeware Discovery studio from 
Accelrys Inc. (a) A total of 6 unique mutations thus observed among the known 
CTA sequences (Table 2) from several serogroups are shown at their 
corresponding 6 residue positions using the Corey-Pauling-Kultun (CPK) 
residue model representation. (b)  Fourteen unique mutations thus observed 
among the known CTB sequences (Table 3) from several serogroups are 
shown at their corresponding 13 residue positions using the CPK residue model 
representation. 
 
 
Figure 8: Structural models of CTA (a) and CTB (b) subunits with known 
mutations at the respective structural interfaces or solvent accessible regions in 
the complex among archived serogroups. We used the structure with PDB entry 
(1XTC) for generating this visual using the freeware Discovery studio from 
Accelrys Inc. (a) A total of 6 unique mutations thus observed among the known 
CTA sequences (Table 4) from several serogroups are shown at their 
corresponding 6 residue positions using the CPK residue model representation. 
All of these 6 mutated positions are present at the solvent exposed regions of 
CTA in both monomer and CTA/CTB complex state. (b) A total of 7 out of 14 
unique mutations thus observed among the known CTB sequences (Table 4) 
from several serogroups are shown at their corresponding 7 (3, 15, 25, 34, 47, 
52 and 60) out of the 13 residue positions using the CPK residue model 
representation are at the CTB/CTB interfaces in the B5 complex. 
 
Protein-Protein interfaces are formed between A and B5 as well as within B5. 
The mutations in A and B will potentially affect A/B5 interface (Figure 1). B5 
is a homo-pentamer and each B subunit is juxtaposed with similar CTB units 
on either side (Figure 5). Similarly, mutations within B will possibly affect the 
formation of B5 such that the D-E and D-H interfaces are affected (Figure 5). 
Nevertheless, these interfaces should be translated into sequence positions 
using ∆ASA in solved CT structures as described in Figure 6. Moreover, Fig. 6 
maps the mutations in CTA to their occurrence at the CTA/CTB interface 
(Figure 6a) and in CTB to their possible occurrence at the D-E and D-H 
interfaces  (Figure 6b and 6c) in B5. This comparison helps to identify the 
presence of mutated residues (Figure 7) in CTA (Figure 7a) and CTB (Figure 
7b) at their respective CTA/CTB (Figure 8a) interface and CTB/CTB (Figure 
8b) interfaces. The 6 mutations (R7W, S28N, E112G, V134G, G163R and 
I222Y) in CTA are positioned at the solvent exposed regions of the subunit 
(Figure 6) with no mutations at the CTA/CTB interface. However, it should be 
noted that the S28N and I222Y mutation were closely located to the CTA/CTB 
interface (Table 4). The role of these mutations in CT complex assembly is of 
interest. A number of mutations in the CTB sequence are positioned at the 
CTB/CTB interfaces unlike the mutations in CTA sequence. The mutations at 
residue positions 3, 15, 25, 34, 47, 52 and 60 are within CTB/CTB interfaces 
(Figure 8). The nature of amino acid mutations in CTA and CTB among 
O1/O139 and non-(O1/O139) serogroups are given in Table 4 (see 
Supplementary material). 
 
Discussion: 
Choleragen (CT) and Choleragenoid (CTB) have been used as cholera vaccine 
candidates [47]. A number of subunit vaccine candidates using CTA ((S63K, 
R192G, R192N) [48], (I16A or V72Y, I16A+Y68S, V72Y+Y68S) [49], 
(V53D, V53E, V53Y, S63K, V97K, V97Y, Y104K, Y104D, Y104S, P106S) 
[50]) mutants and CTB recombinants have been developed in addition to heat 
killed attenuated Vibrio cholerae as vaccines. Sequence and structural studies 
of CT offer tremendous opportunity for the improvements in vaccine candidate 
design and development. The presence of CT epitypes [51] and heterogeneity 
in CTB subunit [52] also need to be considered from a vaccine perspective. A 
vaccine for cholera must target O1, O139 as well as non-O1 and non-O139 
strains to have effective control over cholera outbreaks. Moreover, different 
serogroups of non-(O1/O139) strains (with ctxAB genes [25, 41, 53, 54]) and 
newly emerging Vibrio cholerae strains (O1 Matlab [55-57], O1 El Tor with 
altered CTB [58, 59]) must be taken into consideration in cholera vaccine 
design. Hence, comparison studies on CTA and CTB sequences from various 
Vibrio cholerae serogroups provide insights in developing an effective toxin 
analog for vaccine design against multi serogroups.  
 
A number of sequence comparison studies show CT sequence homology 
among various Vibrio cholerae serogroups. Recently, Kumar et al. (2009) 
documented a new CT variant of the Vibrio cholerae O1 El Tor biotype 
isolated from Orissa (India) [60]. The study highlighted a novel mutation 
(H20N) in CTB and the presence of altered CTB of the Classical biotype in the 
El Tor clinical isolates.  Raychoudhuri and team (2009) conducted a study to 
attest the replacement of El Tor biotype ctxB allele by Classical biotype ctxB 
allele in O1 strains [61]. A study by Ansaruzzaman and colleagues (2004) 
reported H18Y and T47I substitutions in CTB of El Tor strain and these 
sequences are similar to CTB of Classical biotype [62]. Previously, a study 
demonstrated the emergence of new El Tor strains with a modified Classical 
biotype CT [60]. Thus, a dataset of sequences (Table 1) for CTA and CTB 
representing diverse serogroups isolated at various periods of time from a 
variety of sources and locations available in GenBank (release 177) is created 
for this study. The nature of mutations (Table 4) among the serogroups is 
presented for CTA (Table 2) and CTB (Table 3) sequences. Several studies 
have demonstrated the effects of site directed mutations in CTA as well as in 
CTB subunits for the wild type O1 strain (Table 5 see Supplementary 
material).  Manufactured site directed mutants leading to decrease or loss in 
toxicity has been reported for CTA (R7K, R11K, I16A, R25G, E29H, S68Y + 
V72Y, E112Q, F223D) and CTB (R35D, H57A, L77D, I74D, T78D). Thus, 
the role of site directed mutants in the loss of toxicity is known for the wild 
type O1 strain. Therefore, it is important to evaluate the effect of mutations 
caused by natural selection pressure among serogroups.  
 
The multiple sequence alignment (MSA) of these sequences showed mutations 
in CTA (at six residue positions such as 7, 28, 112, 134, 163 and 222) and CTB 
(at 13 residue positions such as 3, 7, 13, 15, 18, 22, 25, 34, 46, 47, 52, 60 and 
94) among O1/O139 and non-(O1/O139) strains. The effects of these mutations 
in the formation of a clinically functional cholera toxin (AB5 hetero-hexamer) 
are of significant importance. Reports describing the emergence of new 
serogroups with novel mutations in CTA and CTB are available. However, 
studies on the effects of mutations in CT relative to CTA/CTB-pentamer 
interface (Figure 1) and within CTB/CTB interfaces (Figure 5) are not yet 
available. Here, we present results of a comprehensive analysis of mutations in 
CTA and CTB sequences from several serogroups (Table 4).  
 
This mutational data is presented relative to A/B5 and CTB/CTB interfaces for 
AB5 assembly to understand its functions. Data suggest the presence of 
mutations in CTA (Figure 8a) and CTB (Figure 8b) at the solvent exposed, 
interior, subunit interface regions of the complex. The mutations (at 6 residue 
positions such as 7, 28, 112, 134, 163 and 222) in CTA are located at 
structurally solvent exposed regions of the subunit. However, several mutations 
(7 residue positions such as 3, 15, 25, 34, 47, 52 and 60) in CTB are at the B5 
homo-pentamer subunit interfaces. Thus, the role of these mutations in CTA 
and CTB towards the assembly of AB5 CT among the O1/O139 and non-BIOINFORMATION  open access 
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(O1/O139) strains is inferred from this study (Figure 7 and 8). It should also be 
noted that some of these mutations (polar to non-polar or vice versa) are largely 
non-synonymous (causing physical and chemical property shift) in nature and 
have potential effect on protein-protein interactions of the CT subunits 
affecting AB5 formation (Table 5). Thus, data presented in Table 4 is all-
inclusive, updated, relevant and specific for several known serogroups. This is 
of significance towards the improvement of recombinant CT protein complex 
analogs for vaccine design against multi serogroups. 
 
Conclusion: 
The structural role of cholera toxin in pathogenesis is known for the wild type 
O1 strain. It was of interest to document its role in other known serogroups 
showing mutations with the wild type. We described the structural location of 
such mutations in the known serogroups to infer its functional role. We 
documented that mutations in CTA are at the solvent exposed regions of the 
AB5 complex, while those in CTB are at the CTB/CTB interface of the homo-
pentamer complex. It is observed that these mutations are also non-
synonymous (i.e. polar to non-polar or vice versa) in property. Thus, the effect 
of these mutations in the AB5 assembly is inferred. It is also of global 
importance to quantify precisely the structural effects caused by these 
mutations. The resulting data is relevant in designing a recombinant CT protein 
complex analog for vaccine design against multiple serogroups. Coupled to 
these analyses, it may be stated also that from a clinical perspective, the task of 
enhancing oral cholera vaccines entails reducing bacterial and Giardia infection 
and improving diet [63].  
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Supplementary material: 
 
Table 1: Dataset summary for CTA and CTB sequences from various serogroups 
Serogroups  Number of sequences 
 Biotypes  CTA  CTB 
O1 El Tor  8  113 
O1 Classical  6  3 
O1 
O1 Matlab  0  5 
O139 -  5  37 
Non O1/O139  -  8  7 
Total 27  165 
 
Table 2: Mutations in CTA sequences among different serogroups as summarized from MSA. 
Strain Sero-
group 
Sero-type Length No.  of  mutated  residues Mutation Accession  number 
4260B O139  O139  46  1  I222Y  CAA53975 
B -  188  2  R7W,  E112G  AAR29797 
J31W -  258  3  S28N, V134G, G163R  ACU00910 
203-93  O141 258  1  S28N  AAL69945 
571-88  O115 258  1  S28N  AAL69944 
1322-69  O37 258  1  S28N  AAL60525 
S7 
 
 
 
non 
O1/O139 
O37 258  1  S28N  BAA06288 
 
Table 3: Mutations in CTB sequences among different serogroups as summarized from MSA.  
Strain Serogroup  Biotype/Serotype  Length  No. of mutated residues  Mutation  Accession 
N 16961  O1   El Tor  124  2  H18Y,T47I  AAF94613 
2125  O1   El Tor  124  2  H18Y,T47I  CAA41593 
169/12  O1   El Tor  123  1  H13P  ACH70469 
204/12  O1   El Tor  123  1  H13P  ACH70470 
319/03  O1   El Tor  123  3  H13P, H18Y, T47I  ACH70468 
337/01  O1   El Tor  123  1  H13P  ACH70472 
354/02  O1   El Tor  123  3  H13P, H18Y,T47I  ACH70467 
365(2)  O1   El Tor  124  1  F25L  ACF35009 
366(1)  O1   El Tor  124  1  F25L  ACF35007 
6732/80  O1   El Tor  124  1  F25L  ACF35008 
120186  O1   El Tor  124  1  F25L  ACF35006 
BX 330286  O1   El Tor  124  1  F25L  ACF35005 
Cis 77  O1   El Tor  124  1  F25L  ACF35010 
Peru-044  O1   El Tor  115  2  H18Y,T47I  ACH70463 
Peru-130  O1   El Tor  123  2  H18Y,T47I  ACH70464 
Peru-296  O1   El Tor  123  2  H18Y,T47I  ACH70465 
KSQM03  O1   El Tor  123  3  H18Y,T47I, S60L  ABV74277 
KSQM04  O1   El Tor  123  1  S60L  ABV74281 
KSQM05  O1   El Tor  123  2  H18Y,T47I  ABV74273 
KSQM10  O1   El Tor  123  2  H18Y,T47I, S60L  ABV74278 
KSQM11  O1   El Tor  123  3  H18Y,T47I, S60L  ABV74282 
KSQM16  O1   El Tor  123  1  S60L  ABV74283 
KSQM21  O1   El Tor  123  3  H18Y,T47I, S60L  ABV74274 
KSQM22  O1   El Tor  123  3  H18Y,T47I, S60L  ABV74284 
KSQM48  O1   El Tor  123  2  H18Y,T47I  ABV74285 
KSJ05  O1   El Tor  123  2  H18Y,T47I  ABV74280 
KSZ337/01  O1   El Tor  123  2  H18Y,T47I  ABV74276 
KSZ280/02  O1   El Tor  123  2  H18Y,T47I  ABV74275 
KSZ20/03  O1   El Tor  123  1  V52G  ABV74279 
B65 O1    Mozambique  104  2  H18Y,T47I  AAV54184 
MG116226 O1    Matlab  104  2  H18Y,T47I  ABG56879 
MG116025 O1  Matlab  104  2  H18Y,T47I  ABG56881 
1854 O139  -  124  2  H18Y,T47I  BAA06291 
AJ_937 O139  -  124  2  H18Y,T47I  ACV81827 
AK_31047 O139  -  124  2  H18Y,T47I  ACV81828 
AL_1852 O139  -  124  2  H18Y,T47I  ACV81826 
MP_1950 O139  -  124  1  D7A  ACV81829 
MP_2044 O139  -  119  1  D7A  ACV81853 
NHCM297 O139  -  124  2  H13P,  H18Y  ACV81847 
2205769 O139  -  124 1  D7A  ACV81837 BIOINFORMATION  open access 
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2202931 O139  -  124 1  D7A  ACV81825 
2203098 O139  -  124 1  D7A  ACV81836 
5777_97 O139  -  124 2  H18Y,T47I  ACV81833 
7371/98 O139  -  124 1  D7A  ACV81822 
4260B O139  -  124  2  H18Y,T47I  CAA53973 
J31W non  O1/O139  -  124  6  H13N,H18Y,D22E,F25L, 
A46E, H94N 
ACU00911 
365-96  non O1/O139  O27  104  2  Q3H, D7A  AAM22587 
63  non O1/O139  O26  124  2  Q3H, D7A  AAL6052 
1300-69  non O1/O139  O37  124  2  F25L, K34N  AAL60524 
S7  non O1/O139  O37  124  2  F25L, K34N  BAA06289 
506-94  non O1/O139  O44  124  2  Q3H, D7A  AAL69946 
571-88  non O1/O139  O105  123  4  T15A, H18Y, F25L, 
K34N 
AAL60523 
  
Table 4: Mutations, their sequence positions, change in amino acid types, relative occurrence at surface, interface, interior regions of the complex in different 
serogroups is given.  
   Mutation  Nature of 
Mutations 
No. of 
Strains  CTA/CTB interface  Buried  Exposed  Strain(s) 
O1/O139  I222Y  Non polar to 
Non polar  1     9  4260B 
R7W  Polar(+) to 
Non polar  1     9 B 
S28N  Polar(0) to 
Polar(0)  5     9  J31W, 203-93, 571-88, 1322-69, 
S7 
E112G  Polar(-) to 
Non polar  1     9 B 
V134G  Non polar to 
Non polar  1     9 J31W 
CTA 
Non-
(O1/O139) 
G163R  Non polar to 
Polar(+)  1     9 J31W 
  CTB/CTB 
interface 
CTB/CTA 
interface  Buried Exposed  Strains(s) 
D7A  Polar(-) to 
Non polar  6  9      MP1950, MP2044, 2205769, 
2202931, 2203098, 737198 
H13P  Polar(+) to 
Polar(0)  6       9  169/12, 204/12, 319/03, 337/01, 
354/02, NHCM297 
H18Y  Polar(+) to 
Non polar  27       9 
N16961, 2125, 319/03, 354/02, 
Peru044, Peru130, Peru296, 
Moz, KSMQ03, KSMQ05, 
KSMQ10, KSMQ11, KSMQ21, 
KSMQ22, KSMQ48, KSJ05, 
KSZ337/01, KSZ280/02, 
MG116226, MG116025, 1854, 
AJ937, AK31047, AL1852, 
NHCM297, 577797, 4260B 
F25L  Non polar to 
Non polar  6  9      365/02, 366/01, 6732/80, 
120186, BX330286, Cis77 
T47I  Polar(0) to 
Non polar  23  9      
N16961, 2125, 319/03, 354/02, 
Peru044, Peru130, Peru296, 
Moz, KSMQ03, KSMQ05, 
KSMQ10, KSMQ11, KSMQ21, 
KSMQ22, KSMQ48, KSJ05, 
KSZ337/01, KSZ280/02, 
MG116226, MG116025, 1854, 
AJ937, AK31047, AL1852, 
577797, 4260B 
V52G  Non polar to 
non polar  1  9       KSZ20/03 
O1/O139 
S60L  Polar(0) to 
Non polar  7  9     
KSMQ03, KSMQ04, KSMQ10, 
KSMQ11, KSMQ16, KSMQ21, 
KSMQ22 
Q3H  Polar(0) to 
Polar(+)  3  9      O26_63, O27_365/96, 
O44_506/94 
CTB 
Non-
(O1/O139) 
D7A  Polar(-) to 
Non polar  3  9      O26_63, O27_365/96, 
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ISSN 0973-2063 (online) 0973-8894 (print)     
Bioinformation 6(1): 1- 9 (2011)                          © 2011 Biomedical Informatics 
 
 
9
H13N  Polar(+) to 
Polar(0)  1       9  J31W, 
T15A  Polar(0) to 
Non polar  1  9      O105_571/88 
H18Y  Polar(+) to 
Non polar  2       9 J31W,  O105_571/88 
D22E  Polar(-) to 
Polar(-)  1       9 J31W 
F25L  Non polar to 
Non polar  4  9      J31W, O37_1300/69, 
O37_S7,O105_571/88 
K34N  Polar(+) to 
Polar(0)  3  9       O37_1300/69, 
O37_S7,O105_571/88 
A46E  Non polar to 
Polar(-)  1       9 J31W 
H94N  Polar(+) to 
Polar(0)  1       9 J31W 
 
Table 5: Function inference to known site directed mutants with corresponding relative occurrence at surface, interface, interior regions of the complex is given. 
 Mutation  Inference  Reference  CTA/CTB interface  Buried Exposed  Partially 
buried 
R7K ADP-ribosyl-
transferase activity 
of CTA disrupted 
Burnette et al. (1991), 
Hase et al. (1994), 
Chan et al. (2010) 
[64,65,66]       9 
R11K Reduced  toxicity      9   
I16A       9 
R25G     9   
E29H  9    9   
Y30W,A,H       9 
S68Y + V72Y     9   
E110D 
Reduced toxicity 
and enzymatic 
activity 
 
Jobling & Holmes (2001) 
 
[67] 
   9   
E112D Reduced  toxicity 
and enzymatic 
activity 
Hase et al. (1994), 
Jobling & Holmes (2001), 
Chan et al. (2010) 
[65,66, 67]       9 
CTA 
F223D Reduced  stability 
and toxicity 
Tinker et al. (2003)  [68]  9    9   
   CTB/CTB 
interface 
CTB/CTA 
interface 
Buried Exposed  Partially 
buried 
V10A Affects 
immunoreactivity 
Jobling & Holmes (2002)  [69]      9   
G33E Over  expressed 
CTB diminishes 
active CT 
production 
Silva et al. (1998)  [70]      9   
G33D Abolish  receptor 
binding ability 
    9   
R35D Reduced  AB5 
assembly 
Merritt et al. (1995)  [71] 
    9   
V46A Affects 
immunoreactivity 
Jobling & Holmes (2002)  [69]      9   
H57A  Loss of toxicity  Aman et al. (2001)  [72]      9   
L74D No  AB5 formation  9  9     
I77D No  B5 assembly  9  9     
CTB 
T78D No  AB5 assembly 
Tinker et al. (2003)  [68] 
9  9     
 